Emerging potential of 5-Fluorouracil-loaded chitosan nanoparticles in cancer therapy

Dongsar, Tenzin Tsering; Dongsar, Tenzin Sonam; Gupta, Neelima; Almalki, Waleed H.; Sahebkar, Amirhossein; Kesharwani, Prashant

doi:10.1016/j.jddst.2023.104371

Cited by 28 publications

(16 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[47] The chitosan nanoparticles containing 5-Fluorouracil emerged great potential in cancer therapy. [48] Studies on chitosan nanoparticles for formulation and oral delivery have demonstrated their effectiveness in enhancing drug uptake and promoting gene expression. [49] For example, chitosan nanoparticles mediated silencing of LncRNA TMEM44-AS1 activated the P53 signaling pathway and reversed resistance in gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Chitosan‐Low Molecular Weight Heparin Sodium Nanoparticles Regulate Treg/Th17 Immune Balance and Inflammation at the Maternal‐Fetal Interface to Ameliorate Pre‐Eclampsia by HB‐EGF

Peng

Xiao

Zhang

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Pre‐eclampsia is a major cause of maternal and fetal mortality. Low molecular weight heparin sodium (LMWH) reduced the incidence of pre‐eclampsia, may be an effective treatment of pre‐eclampsia. But the underlying mechanism of LMWH is unknown. To improve the molecular utilization rate, chitosan‐LMWH nanoparticles (CHsN) are purchased for the study. The prague of pregnancy Sprague‐Dawley rats are injected with nitroso l‐arginine methyl ester to construct a pre‐eclampsia model. Trichotrophoblast cells HTR‐8/SVneo are cultured under Hypoxia/reoxygenation injury (H/R) simulation conditions to construct the cell model. CHsN ameliorates the integrity of fetal membrane tissue. Administration of CHsN results in decreased urine protein and HB‐EGF levels, accompanied by increased numbers of pups and placenta. Treatment with CHsN increases the proportion of Treg cells and decreases the proportion of Th17 cells. After treatment with CHsN, the levels of LPS, TNF‐α, rank1, slp1, Foxo, NF‐κB, and HIF‐1α are down‐regulated, while the levels of IL‐2, Foxp3, and TGFβ1 are up‐regulated. CRM197 reverses the effect of CHsN. The CHsN improves H/R‐induced HTR‐8/SVneo cells apoptosis through HB‐EGF and affected CD4+T cell differentiation. CHsN ameliorates pre‐eclampsia by regulating Treg/Th17 immune balance and inflammation at the maternal‐fetal interface through HB‐EGF. This provides a theoretical reference for relieving pre‐eclampsia by CHsN.

show abstract

Section: Discussionmentioning

confidence: 99%

Chitosan‐Low Molecular Weight Heparin Sodium Nanoparticles Regulate Treg/Th17 Immune Balance and Inflammation at the Maternal‐Fetal Interface to Ameliorate Pre‐Eclampsia by HB‐EGF

Peng

Xiao

Zhang

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…6,7 Additionally, the non-specificity of chemotherapeutics leads to serious adverse effects that harm healthy cells. 8 To improve the survival rate of NSCLC patients, individualized treatment is preferred. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), a new type of molecularly targeted therapy, may stop lung tumors with EGFR mutations from growing and spreading.…”

Section: Introductionmentioning

confidence: 99%

“…Current treatments for non‐small cell lung cancer, including surgery, chemotherapy, and radiotherapy, are insufficient to reduce the high mortality rates 6,7 . Additionally, the non‐specificity of chemotherapeutics leads to serious adverse effects that harm healthy cells 8 . To improve the survival rate of NSCLC patients, individualized treatment is preferred.…”

Section: Introductionmentioning

confidence: 99%

Network‐based identification of key proteins and repositioning of drugs for non‐small cell lung cancer

Adeyemo,

Ashimiyu‐Abdusalam,

Adewunmi

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundNSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment.AimsThis study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach.MethodsDifferentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co‐expression was developed with the aim of detecting two modules of gene co‐expression. Following that, the Drug–Gene Interaction Database was used to find possible drugs that target important genes within two gene co‐expression modules linked to non‐small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug–gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs.ResultsUnlike previous research on repositioning drugs for NSCLC, which uses a gene co‐expression network, this project is the first to research both gene co‐expression and co‐occurrence networks. And the co‐occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non‐small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug–gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib.ConclusionHence, there is a possibility of repurposing these drugs for the treatment of non‐small‐cell lung cancer.

show abstract

“…Cancer cells differ from normal cells in many ways, one of which is that they grow and divide very rapidly. In response to this characteristic, a number of cytotoxic drugs have been developed that target rapidly proliferating cancer cells and inhibit their growth and proliferation by interfering with their DNA synthesis or cell division processes ( McQuade et al, 2017 ; Dongsar et al, 2023 ). However, cytotoxic drugs do not completely discriminate between cancer cells and normal cells ( Tofzikovskaya et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Microwave biosensor for the detection of growth inhibition of human liver cancer cells at different concentrations of chemotherapeutic drug

Zhao,

Wang,

Shi

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cytotoxicity assays are crucial for assessing the efficacy of drugs in killing cancer cells and determining their potential therapeutic value. Measurement of the effect of drug concentration, which is an influence factor on cytotoxicity, is of great importance. This paper proposes a cytotoxicity assay using microwave sensors in an end-point approach based on the detection of the number of live cells for the first time. In contrast to optical methods like fluorescent labeling, this research uses a resonator-type microwave biosensor to evaluate the effects of drug concentrations on cytotoxicity by monitoring electrical parameter changes due to varying cell densities. Initially, the feasibility of treating cells with ultrapure water for cell counting by a microwave biosensor is confirmed. Subsequently, inhibition curves generated by both the CCK-8 method and the new microwave biosensor for various drug concentrations were compared and found to be congruent. This agreement supports the potential of microwave-based methods to quantify cell growth inhibition by drug concentrations.

show abstract

Emerging potential of 5-Fluorouracil-loaded chitosan nanoparticles in cancer therapy

Cited by 28 publications

References 151 publications

Chitosan‐Low Molecular Weight Heparin Sodium Nanoparticles Regulate Treg/Th17 Immune Balance and Inflammation at the Maternal‐Fetal Interface to Ameliorate Pre‐Eclampsia by HB‐EGF

Chitosan‐Low Molecular Weight Heparin Sodium Nanoparticles Regulate Treg/Th17 Immune Balance and Inflammation at the Maternal‐Fetal Interface to Ameliorate Pre‐Eclampsia by HB‐EGF

Network‐based identification of key proteins and repositioning of drugs for non‐small cell lung cancer

Microwave biosensor for the detection of growth inhibition of human liver cancer cells at different concentrations of chemotherapeutic drug

Contact Info

Product

Resources

About